Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
Các tác động đa dạng của statin trong mạch máu có dự đoán vai trò trong các bệnh viêm nhiễm?
Tóm tắt
Các tác động đa dạng hiện đang được mô tả cho các chất ức chế 3-hydroxy-3-methylglutaryl-coenzyme A reductase (hay còn gọi là statin), có thể có tính hữu dụng trong bối cảnh bệnh tự miễn viêm mãn tính. Ở đây, chúng tôi thảo luận về dược lý và các ứng dụng đã được thiết lập của statin và trong ngữ cảnh này mô tả các tác động tiềm năng chống viêm và điều chỉnh miễn dịch. Một tập hợp dữ liệu in vitro rộng lớn xác định vai trò của statin trong việc điều chỉnh chức năng nội mô, đặc biệt là về sự biểu hiện của các phân tử gắn kết và sự chết tế bào theo chương trình. Những tác động rộng hơn đối với chức năng của bạch cầu hiện đã xuất hiện bao gồm sự thay đổi trong biểu hiện các phân tử gắn kết, sự giải phóng cytokine và chemokine, và điều chỉnh sự phát triển của phản ứng miễn dịch thích ứng thông qua việc điều chỉnh tăng cường MHC lớp II. Dữ liệu in vivo trong một số mô hình viêm, bao gồm viêm khớp viêm do collagen gây ra và bênh viêm não tự miễn thử nghiệm, cho thấy rằng những tác động như vậy có thể có tiềm năng điều chỉnh miễn dịch. Cuối cùng, một thử nghiệm lâm sàng gần đây đã chứng minh các tác động điều chỉnh miễn dịch của statin ở bệnh nhân viêm khớp dạng thấp. Cùng với các tác động bảo vệ mạch máu đã biết, cơ sở bằng chứng ngày càng lớn này cung cấp sự hỗ trợ thuyết phục cho các thử nghiệm dài hạn hơn về liệu pháp statin trong các bệnh ở người như viêm khớp dạng thấp.
Từ khóa
#statin #tác động đa dạng #bệnh viêm #điều chỉnh miễn dịch #viêm khớp dạng thấpTài liệu tham khảo
Hamelin BA, Turgeon J: Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998, 19: 26-37. 10.1016/S0165-6147(97)01147-4.
Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001, 2: 205-207. 10.1186/CVM-2-5-205.
Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y: A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001, 29: 282-288.
Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001, 88: 504-508. 10.1016/S0002-9149(01)01727-1.
Farnier M, Davignon J: Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol. 1998, 82: 3J-10J. 10.1016/S0002-9149(98)00423-8.
Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, et al: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996, 275: 128-133. 10.1001/jama.275.2.128.
Blum CB: Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol. 1994, 73: 3D-11D. 10.1016/0002-9149(94)90626-2.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344: 1383-1389. 10.1016/S0140-6736(94)92521-6.
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995, 333: 1301-1307. 10.1056/NEJM199511163332001.
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002, 360: 7-22. 10.1016/S0140-6736(02)09327-3.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001, 285: 1711-1718. 10.1001/jama.285.13.1711.
Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation. 2002, 105: 1135-1143. 10.1161/hc0902.104353.
Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A: Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001, 77: 247-253. 10.1016/S0167-5273(00)00439-3.
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004, 350: 1387-1397. 10.1056/NEJMoa032804.
Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001, 286: 64-70. 10.1001/jama.286.1.64.
Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002, 87: 563-568. 10.1210/jc.87.2.563.
Seljeflot I, Tonstad S, Hjermann I, Arnesen H: Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis. 2002, 162: 179-185. 10.1016/S0021-9150(01)00696-7.
Li D, Chen H, Romeo F, Sawamura T, Saldeen T, Mehta JL: Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther. 2002, 302: 601-605. 10.1124/jpet.102.034959.
Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T: The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J Atheroscler Thromb. 2002, 9: 178-183.
Wagner AH, Gebauer M, Guldenzoph B, Hecker M: 3-Hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol. 2002, 22: 1784-1789. 10.1161/01.ATV.0000037098.20829.31.
Seljeflot I, Tonstad S, Hjermann I, Arnesen H: Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res. 2002, 105: 285-290. 10.1016/S0049-3848(02)00034-8.
Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G: Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis. 2000, 152: 359-366. 10.1016/S0021-9150(00)00454-8.
Bourcier T, Libby P: HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000, 20: 556-562.
Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J: HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol. 2002, 135: 284-292.
Fenton JW, Jeske WP, Catalfamo JL, Brezniak DV, Moon DG, Shen GX: Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry (Mosc). 2002, 67: 85-91. 10.1023/A:1013956215394.
Mason JC, Ahmed Z, Mankoff R, Lidington EA, Ahmad S, Bhatia V, Kinderlerer A, Randi AM, Haskard DO: Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res. 2002, 91: 696-703. 10.1161/01.RES.0000038151.57577.19.
Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, Mathis D, Benoist C: How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol. 2002, 3: 360-365. 10.1038/ni772.
Yilmaz A, Reiss C, Tantawi O, Weng A, Stumpf C, Raaz D, Ludwig J, Berger T, Steinkasserer A, Daniel WG, et al: HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis. 2004, 172: 85-93. 10.1016/j.atherosclerosis.2003.10.002.
Grip O, Janciauskiene S, Lindgren S: Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes. Inflamm Res. 2002, 51: 58-62.
Hilgendorff A, Muth H, Parviz B, Staubitz A, Haberbosch W, Tillmanns H, Holschermann H: Statins differ in their ability to block NF-κB activation in human blood monocytes. Int J Clin Pharmacol Ther. 2003, 41: 397-401.
Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, Hernandez-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, et al: Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 2002, 160: 49-58. 10.1016/S0021-9150(01)00547-0.
Xu ZM, Zhao SP, Li QZ, Nie S, Zhou HN: Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta. 2003, 338: 17-24. 10.1016/S0009-8981(03)00321-8.
Ruiz-Velasco N, Dominguez A, Vega MA: Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-γ ligands. Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem Pharmacol. 2004, 67: 303-313. 10.1016/j.bcp.2003.09.006.
Choi M, Rolle S, Rane M, Haller H, Luft FC, Kettritz R: Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int. 2003, 63: 96-106. 10.1046/j.1523-1755.2003.00718.x.
de F, Sanchez de Miguel L, Farre J, Gomez J, Romero J, Marcos-Alberca P, Nunez A, Rico L, Lopez-Farre A: Expression of an endothelial-type nitric oxide synthase isoform in human neutrophils: modification by tumor necrosis factor-alpha and during acute myocardial infarction. J Am Coll Cardiol. 2001, 37: 800-807. 10.1016/S0735-1097(00)01185-2.
McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY: A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol. 2004, 172: 2903-2908.
Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med. 2000, 6: 1399-1402. 10.1038/82219.
Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001, 7: 687-692. 10.1038/89058.
McInnes IB, Leung BP, Liew FY: Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells. Arthritis Res. 2000, 2: 374-378. 10.1186/ar115.
Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, et al: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002, 420: 78-84. 10.1038/nature01158.
Hakamada-Taguchi R, Uehara Y, Kuribayashi K, Numabe A, Saito K, Negoro H, Fujita T, Toyo-oka T, Kato T: Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res. 2003, 93: 948-956. 10.1161/01.RES.0000101298.76864.14.
Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, et al: A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003, 170: 1524-1530.
Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, et al: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001, 21: 115-121.
Palmer G, Chobaz V, Talabat D, Taylor S, So A, Gabay C, Busso N: Statins have no effect on collagen-induced arthritis in mice. Arthritis Res Ther. 2004, 100-10.1186/ar1142. Suppl 1
Pahan K, Sheikh FG, Namboodiri AM, Singh I: Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 1997, 100: 2671-2679.
Kumagai K, Nakashima H, Saku K: The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res. 2004, 62: 105-111. 10.1016/j.cardiores.2004.01.018.
Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, Rabb H: Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol. 2003, 23: 13-17. 10.1159/000066301.
Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Cohen AH, Teraski PI, et al: The effect of pravastatin on acute rejection after kidney transplantation – a pilot study. Transplantation. 1996, 61: 1469-1474. 10.1097/00007890-199605270-00010.
Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B, Hammad A, Holme I, Isoniemi H, Moore R, et al: Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int. 2001, 60: 1990-1997. 10.1046/j.1523-1755.2001.00010.x.
Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, Seidel D, Reichart B: Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997, 96: 1398-1402.
Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, et al: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995, 333: 621-627. 10.1056/NEJM199509073331003.
Pasceri V, Yeh ET: A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999, 100: 2124-2126.
Pincus T, Sokka T, Wolfe F: Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 2001, 44: 1234-1236. 10.1002/1529-0131(200106)44:6<1234::AID-ART213>3.0.CO;2-R.
McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N: Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004, 363: 2015-2021. 10.1016/S0140-6736(04)16449-0.